NO316644B1 - Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav - Google Patents
Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav Download PDFInfo
- Publication number
- NO316644B1 NO316644B1 NO19964966A NO964966A NO316644B1 NO 316644 B1 NO316644 B1 NO 316644B1 NO 19964966 A NO19964966 A NO 19964966A NO 964966 A NO964966 A NO 964966A NO 316644 B1 NO316644 B1 NO 316644B1
- Authority
- NO
- Norway
- Prior art keywords
- strains
- cncm
- lactobacillus
- intestinal
- lactobacilli
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 50
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims description 25
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 27
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 230000001575 pathological effect Effects 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 244000052769 pathogen Species 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- 210000000941 bile Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 244000000074 intestinal pathogen Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 101100396933 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) imm2 gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000010544 Bacterial Toxin Neutralization Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 108010042648 lactocin Proteins 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI941073A IT1269838B (it) | 1994-05-26 | 1994-05-26 | Ceppi di lattobacilli di origine umana e loro usi |
| ITMI941773A IT1274733B (it) | 1994-08-25 | 1994-08-25 | Ceppo del genere lactobacillus di origine umana e suoi usi |
| PCT/EP1995/001886 WO1995033046A1 (fr) | 1994-05-26 | 1995-05-18 | Souches de lactobacillus d'origine humaine, leurs compositions et leurs utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964966D0 NO964966D0 (no) | 1996-11-22 |
| NO964966L NO964966L (no) | 1997-01-23 |
| NO316644B1 true NO316644B1 (no) | 2004-03-22 |
Family
ID=26331139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964966A NO316644B1 (no) | 1994-05-26 | 1996-11-22 | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5709857A (fr) |
| EP (1) | EP0760848B1 (fr) |
| JP (1) | JP3653277B2 (fr) |
| CN (1) | CN1094972C (fr) |
| AT (1) | ATE163042T1 (fr) |
| AU (1) | AU686389B2 (fr) |
| BR (1) | BR9507752A (fr) |
| CA (1) | CA2191213C (fr) |
| DE (2) | DE69501591T2 (fr) |
| DK (1) | DK0760848T3 (fr) |
| ES (1) | ES2099056T3 (fr) |
| FI (1) | FI119059B (fr) |
| GR (2) | GR970300016T1 (fr) |
| HU (1) | HU220190B (fr) |
| MX (1) | MX9605807A (fr) |
| NO (1) | NO316644B1 (fr) |
| NZ (1) | NZ287420A (fr) |
| WO (1) | WO1995033046A1 (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN175495A0 (en) * | 1995-03-14 | 1995-04-13 | University Of New England, The | Method and composition for the prevention of the over production of acid |
| AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
| IT1289159B1 (it) | 1997-01-08 | 1998-09-29 | Yurta S R L | Composizioni farmaceutiche e alimentari a base di batteri del genere acetobacter |
| IT1289984B1 (it) * | 1997-02-27 | 1998-10-19 | Proge Farm Srl | Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale |
| IT1299070B1 (it) * | 1998-04-10 | 2000-02-07 | Proge Farm Srl | Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e |
| US7202219B1 (en) * | 1998-02-24 | 2007-04-10 | Md Foods Amba | Use of D-tagatose as a prebiotic food component |
| PT956858E (pt) | 1998-04-30 | 2002-04-29 | Renata Maria Anna Caval Vesely | Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais |
| US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| EP1034788A1 (fr) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Souches de bacteries lactiques capables de prevenir la diarrhée |
| EP1034787A1 (fr) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Souches de lactobacillus capables de prévenir la diarrhée causée des bactéries pathogènes |
| CZ20013269A3 (cs) | 1999-03-11 | 2002-04-17 | Société des Produits Nestlé S. A. | Bakterie mléčného kvaąení |
| US20040105848A1 (en) * | 1999-04-30 | 2004-06-03 | Natarajan Ranganathan | Enteric dialysis compositions and methods |
| US6641808B1 (en) | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
| US20040166101A1 (en) * | 1999-09-22 | 2004-08-26 | Bojrab Gregory G. | Enchanced composition for treatment of gastrointestinal disorders and hyperlipidemia |
| US6696057B1 (en) | 1999-09-22 | 2004-02-24 | Lacpro Industries, Inc. | Composition and method for treatment of gastrointestinal disorders and hyperlipidemia |
| US6613549B2 (en) | 2000-02-10 | 2003-09-02 | Urex Biotech, Inc. | Probiotic therapy for newborns |
| EP1303256B1 (fr) * | 2000-06-09 | 2009-01-07 | Baylor College of Medicine | Combinaison d'agents antimicrobiens et d'une interference bacterienne servant a enduire des dispositifs medicaux |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| CA2442602A1 (fr) | 2000-12-18 | 2002-08-01 | Probio Health, Llc | Composes probiotiques obtenus a partir d'une souche de lactobacillus casei (ke01) |
| US7214370B2 (en) * | 2000-12-18 | 2007-05-08 | Probiohealth, Llc | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| US7060687B2 (en) * | 2001-02-07 | 2006-06-13 | Genmont Biotechnology Co. | Live vaccines for allergy treatment |
| NO318426B1 (no) * | 2001-10-02 | 2005-04-18 | Neurozym Biotech As | Et materiale for a senke konsentrasjonen av patogene tarmpeptider |
| US8147821B2 (en) * | 2002-02-21 | 2012-04-03 | Grain Processing Corporation | Method for drying biomaterials |
| DE60323734D1 (de) | 2002-03-21 | 2008-11-06 | Bifodan As | Lactobacillus-stämme |
| US20080126195A1 (en) * | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
| CA2547144C (fr) | 2005-05-16 | 2010-02-02 | Grain Processing Corporation | Methode de sechage de milieu filtrant epuise |
| CN101273736B (zh) * | 2007-03-28 | 2012-08-08 | 北京弗蒙特生物技术有限公司 | 一种在常温下保持高活菌数的发酵乳的制备方法 |
| PL2016834T3 (pl) * | 2007-07-13 | 2010-04-30 | Unilever Nv | Produkt żywnościowy zawierający bakterie i sorbitolowy ester kwasu tłuszczowego |
| US20090041727A1 (en) * | 2007-08-08 | 2009-02-12 | Conjugon, Inc. | Compositions and Methods for Microbe Storage and Delivery |
| US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| WO2010008491A2 (fr) * | 2008-06-25 | 2010-01-21 | Ritter Natural Sciences, Llc | Compositions de lactose ayant une teneur réduite en lactose |
| KR101003149B1 (ko) * | 2008-10-31 | 2010-12-22 | 전남대학교산학협력단 | 병변 치료용 박테리아 기반의 마이크로로봇 |
| EP2206506A1 (fr) | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Formulations probiotiques |
| WO2010098822A1 (fr) | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Formulations prébiotiques et méthodes d'utilisation |
| EP2248908A1 (fr) | 2009-05-05 | 2010-11-10 | Eurolactis Group S.A. | Micro-organismes probiotiques isolés du lait d'ânesse |
| WO2011009848A2 (fr) | 2009-07-20 | 2011-01-27 | Bracco Spa | Utilisation thérapeutique de probiotiques |
| EP3202406A1 (fr) | 2010-04-28 | 2017-08-09 | Ritter Pharmaceuticals, Inc. | Formulations prébiotiques et méthodes d'utilisation |
| US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10265350B2 (en) | 2012-09-25 | 2019-04-23 | Universidad De Leon | Probiotic and prebiotic compositions |
| CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| KR102358879B1 (ko) | 2015-05-22 | 2022-02-08 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| WO2018071537A1 (fr) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions et méthodes pour traiter la sclérose en plaques et des troubles associés |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (fr) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions et procédés pour traiter la cholangite sclérosante primitive et des troubles associés |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| WO2018187464A1 (fr) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions et méthodes pour traiter la diverticulite et des troubles associés |
| CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
| AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| EP3856212A1 (fr) | 2018-09-27 | 2021-08-04 | Finch Therapeutics Holdings LLC | Compositions et méthodes de traitement de l'épilepsie et de troubles apparentés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
| US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
| ATE153063T1 (de) * | 1992-07-06 | 1997-05-15 | Nestle Sa | Milchbakterien |
-
1995
- 1995-05-18 MX MX9605807A patent/MX9605807A/es unknown
- 1995-05-18 DE DE69501591T patent/DE69501591T2/de not_active Expired - Lifetime
- 1995-05-18 ES ES95920830T patent/ES2099056T3/es not_active Expired - Lifetime
- 1995-05-18 CN CN95193239A patent/CN1094972C/zh not_active Expired - Fee Related
- 1995-05-18 BR BR9507752A patent/BR9507752A/pt not_active IP Right Cessation
- 1995-05-18 CA CA002191213A patent/CA2191213C/fr not_active Expired - Fee Related
- 1995-05-18 AU AU26139/95A patent/AU686389B2/en not_active Ceased
- 1995-05-18 AT AT95920830T patent/ATE163042T1/de active
- 1995-05-18 DK DK95920830T patent/DK0760848T3/da active
- 1995-05-18 HU HU9603251A patent/HU220190B/hu not_active IP Right Cessation
- 1995-05-18 EP EP95920830A patent/EP0760848B1/fr not_active Expired - Lifetime
- 1995-05-18 DE DE0760848T patent/DE760848T1/de active Pending
- 1995-05-18 WO PCT/EP1995/001886 patent/WO1995033046A1/fr active IP Right Grant
- 1995-05-18 JP JP50024096A patent/JP3653277B2/ja not_active Expired - Fee Related
- 1995-05-18 NZ NZ287420A patent/NZ287420A/en not_active IP Right Cessation
-
1996
- 1996-06-17 US US08/664,447 patent/US5709857A/en not_active Expired - Lifetime
- 1996-11-22 NO NO19964966A patent/NO316644B1/no not_active IP Right Cessation
- 1996-11-25 FI FI964681A patent/FI119059B/fi not_active IP Right Cessation
-
1997
- 1997-05-30 GR GR970300016T patent/GR970300016T1/el unknown
-
1998
- 1998-04-30 GR GR980400957T patent/GR3026758T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2099056T3 (es) | 1998-04-01 |
| HUT75555A (en) | 1997-05-28 |
| AU686389B2 (en) | 1998-02-05 |
| DE760848T1 (de) | 1997-08-28 |
| CA2191213A1 (fr) | 1995-12-07 |
| BR9507752A (pt) | 1997-10-07 |
| GR3026758T3 (en) | 1998-07-31 |
| AU2613995A (en) | 1995-12-21 |
| HU220190B (hu) | 2001-11-28 |
| JP3653277B2 (ja) | 2005-05-25 |
| GR970300016T1 (en) | 1997-05-31 |
| NO964966D0 (no) | 1996-11-22 |
| CA2191213C (fr) | 2008-03-18 |
| FI964681A0 (fi) | 1996-11-25 |
| FI119059B (fi) | 2008-07-15 |
| EP0760848A1 (fr) | 1997-03-12 |
| EP0760848B1 (fr) | 1998-02-04 |
| JPH10500577A (ja) | 1998-01-20 |
| US5709857A (en) | 1998-01-20 |
| DE69501591D1 (de) | 1998-03-12 |
| NO964966L (no) | 1997-01-23 |
| ES2099056T1 (es) | 1997-05-16 |
| HU9603251D0 (en) | 1997-01-28 |
| DE69501591T2 (de) | 1998-06-10 |
| DK0760848T3 (da) | 1998-09-23 |
| CN1094972C (zh) | 2002-11-27 |
| CN1154715A (zh) | 1997-07-16 |
| WO1995033046A1 (fr) | 1995-12-07 |
| ATE163042T1 (de) | 1998-02-15 |
| FI964681A (fi) | 1997-01-08 |
| MX9605807A (es) | 1997-12-31 |
| NZ287420A (en) | 1997-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316644B1 (no) | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav | |
| Maldonado et al. | Lactic acid bacteria isolated from young calves–characterization and potential as probiotics | |
| Victor et al. | Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of Cameroon | |
| Gagnon et al. | In vitro inhibition of Escherichia coli O157: H7 by bifidobacterial strains of human origin | |
| EP1005353B1 (fr) | Preparation pharmaceutique contenant du lactobacillus casei rhamnosus | |
| Sreekumar et al. | Immediate effect of Lactobacillus acidophilus on the intestinal flora and fecal enzymes of rats and the in vitro inhibition of Escherichia coli in coculture | |
| US20110236359A1 (en) | Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria | |
| Tinrat et al. | Isolation and characterization of Lactobacillus salivarius MTC 1026 as a potential probiotic | |
| ITRM20110475A1 (it) | Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e | |
| Miyamoto et al. | Lactobacillus flora in the cloaca and vagina of hens and its inhibitory activity against Salmonella enteritidis in vitro | |
| Strompfová et al. | Lactobacilli and enterococci—potential probiotics for dogs | |
| Pato et al. | Antibiotic resistance and antibacterial activity of dadih originated Lactobacillus casei subsp. casei R-68 against food borne pathogens | |
| WO2008077229A1 (fr) | Inhibition de la croissance de micro-organismes par des bactéries lactiques | |
| Kazuń et al. | In vitro study of Lactobacillus plantarum properties as a potential probiotic strain and an alternative method to antibiotic treatment of fish | |
| Murphy | In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract | |
| ES2296635T3 (es) | Bifidobacteria capaz de prevenir la diarrea. | |
| KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
| Kheadr | Impact of acid and oxgall on antibiotic susceptibility of probiotic Lactobacilli | |
| Gomes et al. | Comparison of antagonistic ability against enteropathogens by G+ and G− anaerobic dominant components of human fecal microbiota | |
| DebMandal et al. | Detection of intestinal colonization of probiotic Lactobacillus rhamnosus by stool culture in modified selective media | |
| US20030077255A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
| Tsai et al. | Toxicity evaluation for an Enterococcus faecium strain TM39 in vitro and in vivo | |
| KR100720025B1 (ko) | 프로바이오틱 유산균 및 이를 포함하는 조성물 | |
| Mandal et al. | Therapeutic potential of Lactobacillus ingluviei ADK10, a newly established probiotic organism against acetaminophen induced uremic rats | |
| RU2364623C2 (ru) | Бактериальный штамм бифидобактерий - продуцент фолиевой кислоты (варианты), его применения и пробиотическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |